

JAN 31 2003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08A (10/01) (modified)

Substitute Form 1449 PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number 09/843,159

Filing Date April 25, 2001

First Named Inventor LUO, Ying

Art Unit 1652

Examiner Name RAO, M.

Sheet 1 of 2

Attorney Docket Number A-68292-2/RMS/DHR; 467802-217

RECEIVED

FEB 03 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
mm	A4	US- 6,455,290 B1	09/24/2002	Berthelsen et al.	
	A5	US- 6,277,613 B1	08/21/2001	De Lange et al.	
mm	A6	US- 6,387,902 B1	05/14/2002	Zhang et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
mm	B8	WO	01/04326 A1	01/18/2001	Berthelsen et al.		<input type="checkbox"/>	<input type="checkbox"/>
	B9	WO	00/77225 A1	12/21/2000	Chi et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

JAN 31 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

09/843,159

Filing Date

April 25, 2001

First Named Inventor

LUO, Ying

Art Unit

1652

Examiner Name

RAO, M.

Attorney Docket Number

A-68292-2/RMS/DHR; 467802-217

RECEIVED

FEB 03 2003

TECH CENTER 1600/2900

Sheet

2

of

2

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
mm	C27	DECKER, P. et al., "An Improved Nonisotopic Test to Screen a Large Series of New Inhibitor Molecules of Poly(ADP-ribose) Polymerase Activity for Therapeutic Applications," Clinical Cancer Research, 5:1169-1172, May 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	C28	RANKIN, P.W. et al., "Quantitative Studies of Inhibitors of ADP-ribosylation <i>in Vitro</i> and <i>in Vivo</i> ," J. Biol. Chem., 264(8):4312-4317, March 1989.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

mm

DATE CONSIDERED

4/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1995, no persons are required

12

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT </div> <div style="text-align: center;"> <i>(use as many sheets as necessary)</i> </div>				<div style="text-align: right;"> RECEIVED NOV 07 2002 TECH CENTER 1600/2900 </div>	
				Application Number	09/843,159
				Filing Date	April 25, 2001
				First Named Inventor	Luo
				Group Art Unit	1653
				Examiner Name	Unknown
Sheet	1	of	3	Attorney Docket Number	A-68292-2/RMS/DHR

[illegible][illegible]

Examiner Signature	<i>mm</i>	Date Considered	4/13/03
--------------------	-----------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/843,159
		Filing Date	April 25, 2001
		First Named Inventor	Luo
		Group Art Unit	1653
		Examiner Name	Unknown
Sheet 2 of 3	Attorney Docket Number	A-68292-2/RMS/DHR	

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm2	C1	Smith et al., "Tankyrase, a poly (ADP-ribose) polymerase at human telomeres," Science, 282(5393):1484-1487 (November 1998).	
	C2	Mera, S., "The role of telomeres in aging and cancer," Br J Biomed Sci, 55(3):221-225 (September 1998).	
	C3	Lux et al., "Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins," Nature, 344(6261):36-42 (March 1990).	
	C4	Bryan et al., "Telomerase and the maintenance of chromosome ends," Curr Opin Cell Biol, 11(3):318-324 (June 1999).	
	C5	Hiyama et al., "Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis," Virchows Arch, 434(6):483-487 (June 1999).	
	C6	Krejc, K., "An in situ study of variant telomeric repeats in human chromosomes," Genomics, 58(2):202-206 (June 1999).	
	C7	Holt et al., "Role of telomerase in cellular proliferation and cancer," J Cell Physiol, 180(1):10-18 (July 1999).	
	C8	Tan, Z., "Intramitotic and intraclonal variation in proliferative potential of human diploid cells: explained by telomere shortening," J Theor Biol, 198(2):259-268 (May 1999).	
	C9	Zhu et al., "Chromosomal mapping of the tankyrase gene in human and mouse", Genomics 57:320-321 (1999)	
	C10	Daly, "The Grb7 Family of Signalling Proteins," Cell. Signal 10(9):613-618 (1998)	
	C11	Janes, et al., "Structural Determinants of the Interaction between the erbB2 Receptor and the Src Homology 2 Domain of Grb7," J Biol Chem 272(13):8490-8497 (1997)	
	C12	Daly, "Take Your Partners, Please - Signal Diversification by the erbB Family of Receptor Tyrosine Kinases," Growth Factors 16:255-263 (1999)	
	C13	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science 247:1306-1310 (1990)	
	C14	Burgess et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," J Cell Bio. 111(5 pt 1):2129-2138 (1990)	
	C15	Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," Nat Genet 21(4):440-443 (1999)	
	C16	Bork, P., "Powers and Pitfalls in sequence analysis: the 70% hurdle," Genome Res 10(4):398-400 (2000)	
mm2	C17	Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular 4th Ed., Springer-Verlay, Berlin, pp. 17-18 (1976)	

Examiner Signature	<i>mm2</i>	Date Considered	4/13/03
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/843,159
				Filing Date	April 25, 2001
				First Named Inventor	Luo
				Group Art Unit	1653
				Examiner Name	Unknown
Sheet	3	of	3	Attorney Docket Number	A-68292-2/RMS/DHE

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	C18	Lazar, et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," Mol Cell Biol 8(3):1247-1252 (1988)	
	C19	Harris et al., "Polycystic kidney disease. 1: Identification and analysis of the primary defect," J Am Soc Nephrol 6(4):1125-1133 (1995)	
	C20	Ahn, et al., "The structural and functional diversity of dystrophin," Nat Genet 3(4):283-291 (1993)	
	C21	Cawthon et al., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," Genomics 9(3):446-460 (1991)	
	C22	Database SWALL:CGA1_XENLA, accession P18606 (Nov. 1990), Cyclin A1	
	C23	Database SWALL:CGB1_XENLA, accession P13350 (Jan 1990), G2/Mitotic-specific Cyclin B1	
	C24	Database SWALL:CGB1_HUMAN, accession P14635 (Apr 1990), G2/Mitotic-specific Cyclin B1	
	C25	Database EMBL:MMAA24592, accession AA124592 (Nov 1996), mp86g12.r1 Soares_thymus_2NbMT Mus musculus cDNA clone similar to gb:M25753 G2/Mitotic-specific Cyclin B1 (Human)	
mm	C26	Database EMBL:HSZZ78609, accession AA373339 (Apr 1997), EST85503 HSC172 cells I Homo sapiens cDNA 5' end similar to cyclin B, mRNA sequence	

Examiner Signature	mm	Date Considered	4/13/03
--------------------	----	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.